PTGS2 and colorectal carcinoma: One group of compounds with extensive data supporting their preventive role in cancer onset include the nonsteroidal anti-inflammatory drugs (NSAIDs), shown to reduce the relative risk of developing CRC by 40–50%, mainly by targeting the cyclooxygenase-2 (COX-2) enzyme [5]–[7].